Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
about
B cells as a therapeutic target in autoimmune diseaseSLE - Rituximab in lupusWegener's granulomatosis: current and upcoming therapiesCharacterization of lymphocyte populations in nonspecific interstitial pneumoniaSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesRituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.B cell depletion in autoimmune disease.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Efficacy of remission-induction regimens for ANCA-associated vasculitis.Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab.Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.Challenges in the pursuit of immune tolerance.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabRituximab versus cyclophosphamide for ANCA-associated vasculitis.Immunotherapy for autoimmune and inflammatory renal diseases.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestationsPro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?Prospects for B-cell-targeted therapy in autoimmune disease.Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamideNovel therapies in lupus nephritis.Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.Vasculitis: mechanisms involved and clinical manifestationsB cells as a therapeutic target in autoimmune diseases.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management.Update on diffuse alveolar hemorrhage and pulmonary vasculitis.Clinical use of biologics in vasculitis syndromes.Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.Primary systemic vasculitis: treatment of difficult cases.B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.B lymphocytes as therapeutic targets in systemic lupus erythematosus.Off-label uses of rituximab in dermatology.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trialEffectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisNew indications for biological therapies.
P2860
Q24804504-A4602B36-CE85-43FF-B414-5469ED44E908Q24804739-38152940-2648-4E83-A04C-9429B173A2F6Q24804964-71B4C282-13A3-442E-8CF4-BDADC3CFFF21Q24815753-0C78DE96-C0A8-4A77-B046-4384B9F3B827Q26776308-DE28EDAF-D4B2-4BA2-BFC9-1AF527E20A57Q33359900-072628E6-A892-4A48-8C31-D04174C1A0B8Q33361142-57122CBC-DA2C-4874-BCF8-0B5F48235EB6Q33365619-B8D62766-3CC6-4615-A28B-FAEA159D81F5Q33385389-2A85B6B0-7411-41E3-829C-27C023452259Q34037683-81C2A7A1-794E-4A56-BF01-1906A784B3DEQ34244998-64F1F521-D306-40E5-9731-3AA1A1044CBFQ34369159-4675D07A-1AF2-42EF-BD5D-FDA1DF971EF4Q34974448-4384B804-C6A8-4C6D-8271-F08FC649B2A9Q35065425-F52B50EA-A399-468C-BF36-BD55439E4150Q35109118-CAD71486-0498-4FC5-98D2-7158912053F5Q35144046-56D11347-6C8B-42E4-8D24-8D8ECAEAEF5CQ35557832-5E2CCEFE-7E39-4B84-B2AF-1EE0D5FD9290Q35637406-7B9EA921-DF45-4FA1-9421-4E367A319510Q35777619-93152CA2-5707-4762-A070-E885CCA4EC46Q35824478-8D53CD79-22C7-425C-9F0B-1EB9EB79581CQ35930307-B9510B9E-26C6-49DF-9DB6-F8AA7AA285CAQ35953330-E70FB41B-2DCE-4732-B2EE-8F266123119AQ36054877-7142485C-4FDC-42BF-9110-CA061E2799B2Q36088058-88F47332-0444-4388-9C18-82CF6F3DC363Q36130959-86564D92-1436-4D60-B4DF-23E4CE04D886Q36158684-C1D17FC0-115F-4155-86C9-BF90DB6D3522Q36171750-3F69C403-CF77-4435-BBA7-FBC9A33F8B77Q36234282-8C29A9D5-CDBF-4158-85A3-E8FB769F4AFCQ36354929-FBE0E670-CD17-4293-9272-08029DEFBFD9Q36358081-3C983F9F-C255-4140-A070-CB5097E2EA5DQ36365485-10E7A58A-621D-4F69-AD5C-E9A2E8375F99Q36458145-20EFDE88-C6B1-4B04-B964-91736186CF71Q36577391-D9191EA9-BB47-44F5-ACEC-BAFF3073DC09Q36653646-926C23D3-D681-475E-9F6C-DDDAE33C66B8Q36986050-FD274980-C161-4AD5-A298-92426AB4193BQ37031689-5823C787-9566-48D0-A671-B596047387EDQ37144563-2686075F-68AA-4C80-AAAB-CE709D0299D3Q37546823-1C813673-A06C-4182-B099-6EE5D0795DACQ37640836-3B417761-B27F-44C5-A6DA-E84367617987Q37947157-2AF394C5-D0FA-4A36-ADF0-905EF61ABCA5
P2860
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@en
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@nl
type
label
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@en
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@nl
prefLabel
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@en
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@nl
P2093
P2860
P1476
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
@en
P2093
P2860
P304
P356
10.1002/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W
P577
2001-12-01T00:00:00Z